Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18615479 | 0.85 | EPHX2 (0.53) | EPHX2KMT2AMEN1NPC1RAB9A | |
| SCHEMBL18615444 | 0.85 | KMT2A (0.47) | MAPK14EPHX2KMT2AMEN1NPC1 | |
| SCHEMBL20365336 | 0.84 | EPHX2 (0.52) | EPHX2KMT2AMEN1NPC1RAB9A | |
| SCHEMBL18615489 | 0.83 | MAPK14 (0.44) | MAPK14EPHX2KDM4EPOLB | |
| SCHEMBL20357294 | 0.83 | MAPK14 (0.44) | MAPK14EPHX2KDM4EPOLB | |
| SCHEMBL20976434 | 0.83 | KMT2A (0.47) | EPHX2KMT2AMEN1NPC1RAB9A | |
| SCHEMBL18615611 | 0.81 | MAPK14 (0.43) | MAPK14EPHX2KMT2AGAAKDM4E | |
| SCHEMBL20357312 | 0.81 | MAPK14 (0.43) | MAPK14EPHX2KMT2AGAAKDM4E | |
| SCHEMBL20357281 | 0.79 | MAPK14 (0.42) | MAPK14EPHX2 | |
| SCHEMBL18615639 | 0.79 | MAPK14 (0.42) | MAPK14EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3345893-B1 | UREA DERIVATIVE AND USE THEREFOR | TORAY INDUSTRIES (JP) | 2019-10-30 | — | — | EP | disclosed |
| US-10280145-B2 | Urea derivative and use therefor | TORAY INDUSTRIES, INC. (JP) | 2019-05-07 | — | — | US | disclosed |
| EP-3345893-A1 | UREA DERIVATIVE AND USE THEREFOR | Toray Industries, Inc. (JP) | 2018-07-11 | — | — | EP | disclosed |
| WO-2017038873-A1 | UREA DERIVATIVE AND USE THEREFOR | 東レ株式会社 | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10280145-B2 | Urea derivative and use therefor | UTS2R, DDR1, WEE1 | MAPK14 584/4885EPHX2 4826/4885KMT2A 3875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.